文献速递治疗药物监测与药物基因组学特殊人群用药

药师主导的高管健康项目中药物基因组学服务的实施

Implementation of a pharmacist-provided pharmacogenomics service in an executive health program.
PubMed 文献 · Am J Health Syst Pharm · 2021-01-01

本文描述了在学术医疗中心的高管健康项目(EHP)中实施由药师提供的药物基因组学(PGx)服务。实施包括4个预实施步骤和两次1小时访视。总体策略运行良好,该服务可行,药师有机会主导PGx工作并与医生合作扩大精准医学影响。

要点

  • 药师可在高管健康项目中主导药物基因组学服务,包括检测前教育、结果解读和制定个体化治疗方案。
  • 实施前需完成四步:评估患者人群、选择PGx检测、建立访视结构、选择计费模式。
  • 服务采用两次1小时访视:首次教育并采样,第二次解读结果并讨论PGx指导的治疗计划。

核心结论

  • 在高管健康项目中增加PGx服务是可行的,为药师提供了主导PGx工作并与医生合作扩大精准医学影响的机会。

研究设计与样本

  • 描述性实施报告,地点为科罗拉多大学医院的高管健康项目,团队包括3名医生、1名受训于PGx的药师、1名注册营养师/运动生理学家、1名护士和2名医疗助理。

主要发现

  • PGx咨询包括两次1小时访视:第一次进行检测前PGx教育、审查当前用药和既往药物不耐受、采集DNA样本进行基因分型;第二次药师审查PGx检测结果、个性化PGx报告并与患者讨论PGx指导的治疗计划。
  • 总体策略运行良好,次要挑战包括评估证据有限的基因-药物对、与非EHP提供者沟通信息、排程问题和报销。

临床怎么用

  • 药师可在高管健康项目中建立PGx服务,通过两次1小时访视完成检测前教育、采样、结果解读和个体化治疗计划制定。
  • 实施前应评估患者人群、选择合适的PGx检测、建立访视结构并选择计费模式。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We describe the implementation of a pharmacist-provided pharmacogenomics (PGx) service in an executive health program (EHP) at an academic medical center. SUMMARY: As interest in genomic testing grows, pharmacists have the opportunity to advance the use of PGx in EHPs, in collaboration with other healthcare professionals. In November 2018, a pharmacist-provided PGx service was established in the EHP at the University of Colorado Hospital. The team members included 3 physicians, a pharmacist trained in PGx, a registered dietitian/exercise physiologist, a nurse, and 2 medical assistants. We conducted 4 preimplementation steps: (1) assessment of the patient population, (2) selection of a PGx test, (3) establishment of a visit structure, and (4) selection of a billing model. The PGx consultations involved two 1-hour visits. The first visit encompassed pretest PGx education, review of the patient's current medications and previous medication intolerances, and DNA sample collection for genotyping. After this visit, the pharmacist developed a therapeutic plan based on the PGx test results, discussed the results and plan with the physician, and created a personalized PGx report. At the second visit, the pharmacist reviewed the PGx test results, personalized the PGx report, and discussed the PGx-guided therapeutic plan with the patient. Overall, the strategy worked well; minor challenges included evaluation of gene-drug pairs with limited PGx evidence, communication of information to non-EHP providers, scheduling issues, and reimbursement. CONCLUSION: The addition of a PGx service within an EHP was feasible and provided pharmacists the opportunity to lead PGx efforts and collaborate with physicians to expand the precision medicine footprint at an academic medical center.

来源:Am J Health Syst Pharm,查看原文。版权归原作者所有。

引用

  1. Liko I, Corbin L, Tobin E, et al. Implementation of a pharmacist-provided pharmacogenomics service in an executive health program. Am J Health Syst Pharm. 2021. PMID: 33772264. doi:10.1093/ajhp/zxab137

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。